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Background: This study was aimed at investigating the clinical features and outcomes of follicular lymphoma (FL)
patients younger than 40 years, which have not been extensively investigated yet.
Patients and methods: One hundred and ﬁfty-ﬁve patients younger than 40 years were retrospectively studied from a
series of 1002 FL patients diagnosed in four different European Oncology Centres (Barcelona, Spain; Bellinzona,
Switzerland; London, UK; Novara, Italy) from 1985 to 2010.
Results: Patients younger than 40 had a lower incidence of elevated LDH, high beta2-microglobulin, and a high-risk
Follicular Lymphoma International Prognostic Index (FLIPI) score, whereas bone marrow involvement and bulky and dis-
seminated lymphadenopathy were more frequent. At a median follow-up of 10 years, younger patients, in comparison
with those older than 40, had signiﬁcantly better overall (OS), cause-speciﬁc survival (CSS), and progression-free survival
(PFS), with 10-year OS rate of 81% versus 51% (P < 0.0001), 10-year CSS rate of 82% versus 60% (P < 0.0001), and
10-year PFS of 39% versus 24% (P = 0.0098). However, there were no signiﬁcant CSS and PFS differences in compari-
son with the patients aged 40–60. In multivariate analysis, having the lymphoma diagnosed in the last two decades and a
favourable FLIPI score were associated with a signiﬁcantly longer PFS and CSS in younger patients, whereas only FLIPI
retained statistical signiﬁcance for OS.
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Conclusions: In our series, FL patients younger than 40 have a median OS of 24 years and their outcome seems to be
improving over time. However, they still have a signiﬁcantly shorter life expectancy than that of an age-matched general
healthy population.
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introduction
Follicular lymphoma (FL) typically displays an indolent clinical
course [1–5]. Most patients present with disseminated disease,
nearly all relapse after response to initial therapy, and a pro-
portion experience histological transformation into aggressive
entities [1–5]. Improvement in patient survival has been
reported during the last decades [6–13], mainly due to the add-
ition of rituximab to the treatment options, but also to a better
supportive care.
Approximately half of patients with FL are diagnosed
after the age of 60 years. However, a sizeable proportion of
patients are diagnosed before 40 years: in this context, the
diagnosis of FL could strongly impact on quality and expect-
ancy of life. However, the clinical features and outcomes of
younger adult patients with FL have not been extensively
investigated yet.
The purpose of the present study was to compare, in a large
series of consecutive FL cases diagnosed in the last 25 years in
four European Centres, the clinicopathological characteristics of
patients diagnosed before 40 years of age with those of an older
population.
patients andmethods
The clinical information from adult patients diagnosed with FL between
1985 and 2010 in four European Oncology Institutions (Barcelona, Spain,
n = 366; Bellinzona, Switzerland, n = 255; London, UK, n = 273; Novara,
Italy, n = 108) were collected and merged into a single database. The ﬁnal
database gathered information regarding main demographic (age, gender,
and date of diagnosis) and clinicopathological features [histological grade,
nodal and extranodal involved sites, Ann Arbor stage, Eastern Cooperative
Oncology Group performance status, B symptoms, serum lactate dehydro-
genase (LDH), serum beta2-microglobulin (β2MG), erythrocyte sedimenta-
tion rate (ESR), and bulky disease (deﬁned as >7 cm)], as well as the type of
ﬁrst-line treatment, relapse pattern, and outcome (duration of survival and
cause of death). The FL International Prognostic Index (FLIPI) [14] was cal-
culated, whenever possible, using the recorded information.
Overall survival (OS), cause-speciﬁc survival (CSS), and progression-free
survival (PFS) were deﬁned according to the revised response criteria for ma-
lignant lymphoma [15]. Follow-up was calculated as the median time to cen-
soring using a reverse Kaplan–Meier analysis [16]. Survival probabilities
were calculated using the life-table method, and survival curves were esti-
mated by the Kaplan–Meier method with upper and lower conﬁdence bands
calculated using Greenwood’s approximation; differences between curves
were analysed using the log-rank test (with the trend test as appropriate).
The Cox proportional hazard model was used for uni- and multivariate ana-
lyses and estimation of relative risk and its conﬁdence interval (CI).
Binomial exact 95% CIs were calculated for incidence percentages. Either the
χ2 test or Fisher’s exact test was used for testing associations in two-way
tables, as appropriate; P-values of 0.05 or less (two-sided test) were consid-
ered to indicate statistical difference. Statistical analysis was conducted using
the STATA Release 11 statistical software package (StataCorp 2009, College
Station, TX).
results
patient population
Data were available for 1002 FL patients. Median age at diagnosis
was 56 (range, 21–91) years. One hundred and ﬁfty-two (15%)
patients were younger than 40 years at the time of diagnosis.
A comparison of clinical features at diagnosis between
patients ≤40 and >40 years was carried out using univariate
analysis and is reported in Table 1. Patients <40 years had a
lower incidence of elevated LDH, high β2MG, and a high-risk
FLIPI score, whereas bone marrow involvement, bulky adenopa-
thy (>7 cm), and involvement of more than four nodal lesions
were signiﬁcantly more frequent in this age group.
ﬁrst-line treatment
Forty-two (28%) of the patients younger than 40 and 299 (35%)
of the older were asymptomatic and underwent watchful waiting,
Table 1. Comparison of the main clinicopathological features of
follicular lymphoma patients younger and older than 40 years
Feature Age ≤40
years n (%)
Age >40
years n (%)
P-value
Male sex 72 (47) 380 (45) 0.543
ECOG PS >1 (n = 700) 7 (6) 66 (11) 0.096
B symptoms (n = 861) 26 (18) 109 (15) 0.414
BM involvement 83 (55) 336 (40) 0.001
Era of diagnosis
<1990 27 (18) 106 (12) 0.011
1990–2000 68 (45) 316 (37)
>2000 57 (38) 428 (50)
Stage (n = 920)
I–II 33 (22) 216 (28) 0.140
III–IV 116 (78) 555 (72)
Nodal sites >4 (n = 791) 56 (43) 163 (25) <0.0001
LDH >ULN (n = 834) 18 (14) 160 (23) <0.026
Hb <12 g/dl (n = 872) 19 (15) 118 (16) 0.710
FLIPI (n = 716)
Low-risk (0–1) 65 (55) 242 (40) 0.002
Intermediate (2) 33 (28) 166 (28)
High-risk (3–5) 20 (17) 190 (32)
β2MG >ULN (n = 484) 20 (26) 155 (38) 0.035
ESR >30 mm/h (n = 588) 8 (10) 93 (18) 0.067
Bulk >7 cm (n = 585) 43(46) 90 (18) <0.0001
Histological grade (n = 562)
1 45 (54) 226 (47) 0.463
2 31 (37) 184 (38)
3a 6 (7) 50 (10)
3b 1 (1) 19 (4)
ECOG PS, Eastern Cooperative Oncology Group performance status; BM,
bone marrow; FLIPI, Follicular Lymphoma International Prognostic Index;
LDH, lactate dehydrogenase; ULN, upper level normal; β2MG, beta2-
microglobulin; ESR, erythrocyte sedimentation rate; Hb, haemoglobin.
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deﬁned as deliberate non-intervention for at least 3 months after
diagnosis. Overall, 138 patients (10 of whom younger than 40)
never received any therapy and 40 of them have died.
Lymphoma treatment, according to protocols used at the time,
was eventually given to 862/1000 patients with available data (86%),
including 142 patients younger than 40. Treatment was adminis-
tered immediately to 659 and, when disease became symptomatic,
to 203 of the 341 patients initially managed with watchful waiting.
Information on the type of front-line therapy was recorded in 939
cases (Table 2). The difference in the frequency of treated patients
between those younger than 40 (93%) and those aged 41–60 years
(88%) did not reach a statistical signiﬁcance (P = 0.053), but the
proportion of the treated was signiﬁcantly lower (82%) among
those older than 60 years (P = 0.001).
outcome
The median follow-up was 9.3 years in the overall population,
and 10.7 years for the patients younger than 40 at diagnosis. In
this latter group, 39 patients have died, 34 of them because of
the lymphoma or its treatment toxicity.
The median OS for the whole population was 12.5 years, with a
10-year OS rate of 56% (95% CI 52–60%) and a 20-year OS rate
of 33% (95% CI 28–39%). The median CSS was 17 years, with a
10-year CSS rate of 64% (95% CI 60–68%) and a 20-year CSS rate
of 47% (95% CI 41–53%). The median PFS was 3.9 years, with a
2-year PFS rate of 67% (95% CI 64–70%), a 5-year PFS of 44%
(95% CI 40–47%), and a 10-year PFS of 27% (95% CI 23–30%).
A comparison of survival between different populations accord-
ing to age (under and over 40 years) was carried out. Younger
patients had longer OS, CSS, and PFS. Speciﬁcally, 10-year OS was
81% for patients ≤40 years (95% CI 73–87%) versus 51% in the
older ones (95% CI 46–55%, P < 0.0001); 10-year CSS was 82%
for patients ≤40 years (95% CI 74–87%) compared with 60% in
the older ones (95% CI 56–64%, P < 0.0001; Figure 1). PFS at 2
years was 73% (95% CI 65–79%) for the patients younger than 40
years and 66% (95% CI 63–69%, P = 0.0098) for the older, at
5 years was 49% (95% CI 41–57%) for patients younger than 40,
and 43% (95% CI 39–46%) for the older ones (P = 0.0098). In par-
ticular, 2- and 5-year PFS for the patients younger than 40 diag-
nosed and treated in the last decade were 85% (95% CI 72–92)
and 60% (95% CI 45–73), respectively (Figure 2A).
As summarized in Table 3, when further stratifying patients by
age groups (≤40, 41–59, and ≥60 years old), those ≤40 years old
at diagnosis had longer OS (P = 0.009) compared with those 41–
59 years old, but no differences were detected in PFS and CSS.
No differences in terms of risk of transformation have been
observed (15% of cumulative incidence in both age groups,
P = 0.701). The cumulative incidence of second tumours was 8%
for patients younger than 40 years old, and 11% for the older
ones (P = 0.244).
analysis of prognostic factors
Age ≤40 years, era of diagnosis, presence of B symptoms, high
ESR, elevated serum β2MG, all the variables included in the
FLIPI model [14], and the FLIPI risk stratiﬁcation as a whole had
a signiﬁcant impact on OS, CSS, and PFS on univariate analysis in
the overall population. On multivariate analysis for OS and CSS,
only the FLIPI stratiﬁcation, era of diagnosis, serum β2MG, and
age ≤40 years retained prognostic signiﬁcance; on multivariate
analysis for PFS, the FLIPI stratiﬁcation, era of diagnosis, serum
β2MG, and presence of B symptoms retained prognostic signiﬁ-
cance (data not shown).
The results from univariate analysis for OS, CSS, and PFS, in
the subgroup of patients aged ≤40 years, are summarized in
Table 2. Comparison of first-line treatment type in patients
younger and older than 40 yearsa
Follicular
lymphoma
any age n (%)
Age ≤40
n (%)
Age >40
n (%)
P-value
RT only 72 (8) 14 (10) 58 (7) 0.261
Rituximab 197 (21) 16 (11) 181 (23) 0.003
Alone 33 (4) 3 (2) 30 (4)
Plus chemotherapy 164 (17) 13 (9) 151 (19)
Single-alkylating
agentsb or CVP
297 (32) 44 (31) 253 (32) 0.956
Doxorubicin-
containing regimen
327 (35) 58 (41) 269 (34) 0.075
Purine analoguesc-
containing regimen
72 (8) 11 (8) 61 (8) 0.927
RT, radiotherapy.
aOne hundred and thirty-eight patients initially managed expectantly
and never given anticancer treatments are not included.
bMainly chlorambucil; CVP, cyclophosphamide, vincristine, and prednisone.
cMainly fludarabine.
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Figure 1. Overall survival (A) and cause speciﬁc survival (B) according to age.
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Table 4. On multivariate analysis applied to the population aged
≤40 years, the features signiﬁcantly inﬂuencing CSS and PFS
were the FLIPI risk at diagnosis and era of diagnosis, while only
FLIPI retained statistical signiﬁcance for OS (Tables 5–7).
discussion
Age is a well-known prognostic factor in FL, included in both
the FLIPI [14] and FLIPI2 [17] prognostic indices, and
presentation before the age of 40 years is relatively rare. Indeed,
there are only two published studies speciﬁcally addressing the
characteristics and outcomes of FL in younger adults [18, 19].
However, these reports were either focused on molecular path-
ology or conducted entirely in the pre-rituximab era.
In the present series, the patients younger than 40 years repre-
sented 15% of all FL cases, and this proportion is higher than
those reported from different cancer registries (5%–6% of all FL)
[19, 20]. This difference may reﬂect a different patient selection,
being our cases treated at referral tertiary centres.
Due to the retrospective nature of the analysis and the very
long period of observation, this study has some limitations. The
patients analysed received a large variety of treatment strategies,
with less than half of them receiving rituximab as part of front-
line therapy, and because of the study length, some parameters
were not routinely investigated (e.g. β2MG), resulting in missing
data that might have had an impact on the prognostic analysis.
Nevertheless, the very large number of patients included in this
study allows a reliable description of meaningful clinical features
at presentation and disease outcome.
As expected, the survival of patients aged more than 60 years
is strongly affected by the competing causes of death, but inter-
estingly the CSS of patients younger than 40 years was similar to
that of patients with an age of 41–59 years, suggesting than
younger age at diagnosis does not protect from death due to
lymphoma. In our series, which did not include subjects
younger than 20 years, there were only 9 patients (6%) with age
at diagnosis ≤25 years. These younger patients were not assessed
for the immunohistochemical and molecular markers of the re-
cently described paediatric FL variant [21, 22]; clinically, they
presented a signiﬁcantly higher frequency of localized disease
(55% with stage I–II) in comparison with the rest of the patients
younger than 40 years, but other clinical features at diagnosis
(performance status, β2MG, and FLIPI score) and outcomes
(CSS and OS) were not signiﬁcantly different (data not shown)
from those in patients aged between 25 and 40 years of age. In
the last decade, the survival of patients with FL has been steadily
improving [6–12]. The year of diagnosis was indeed signiﬁcantly
associated with patients’ outcome in our series (supplementary
File, available at Annals of Oncology online). Figure 2B shows
Table 3. Overall survival, cause-specific survival, and progression-free survival by age groups
A Overall survival
Age group N (%) Median (years) 10-year 20-year P-value
≤40 152 (15) 24 81% (95% CI 73–87%) 56% (95% CI 43–68)
41–59 426 (43) 16 68% (95% CI 62–73%) 41% (95% CI 32–49%) ≤40 versus 41–59: 0.009
>60 424 (42) 6 32% (95% CI 27–38%) 13% (95% CI7–21%) ≤40 versus >40: <0.0001
B Cause-specific survival
Age group N (%) Median (years) 10-year 20-year P-value
≤40 152 (15) 24 82% (95% CI 74–87%) 65% (95% CI 52–75%)
41–59 426 (43) Not reached 74% (95% CI 68–79%) 54% (95% CI 44–63%) ≤40 versus 41–59: 0.152
>60 424 (42) 9 44% (95% CI 37–50%) 28% (95% CI 17–39%) ≤40 versus >40: <0.0001
C Progression-free survival
Age group N (%) Median (years) 2-year 5-year P-value
≤40 151 (15) 4.9 73% (95% CI 65–79%) 49% (95% CI 41–57%)
41–59 423 (42) 4.5 71% (95% CI 66–75%) 48% (95% CI 42–52%) ≤40 versus 41–59: 0.196
>60 424 (43) 3.3 62% (95% CI 57–66%) 37% (95% CI 32–42%) ≤40 versus >40: 0.0098
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Figure 2. Progression free survival (A) and cause speciﬁc survival (B) of
patients younger than 40 years according to the year of diagnosis.
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the CSS of patients younger than 40 diagnosed with FL before
or after 2000. Importantly, our data show that younger patients
with FL had a life expectancy superior to 20 years, a useful infor-
mation when counselling younger patients with FL. However,
the long-term prognosis of patients diagnosed with FL before
the age of 60 years remains unsatisfactory. Indeed, while the life
expectancy in the EU for healthy individuals 40 years old is of
42 years (www.eurostat.com; accessed on December 2013), the
projected median OS for younger patients with FL is of 24 years.
In conclusion, in parallel to the global population of patients
with FL, the outcome of younger patients with this type of
lymphoma has been improving over the years. However, the un-
deniable progress in the management of patients with FL has
not resulted in a normal life expectancy for these subjects, with
Table 4. Univariate analysis for OS, CSS, and PFS in the subgroup of patients aged ≤40 years
Features OS CSS PFS
Median (years) P-value Median (years) P-value Median (years) P-value
Sex
Female 19 24 4.7
Male NR 0.245 NR 0.318 7 0.311
ECOG PS
≤1 NR NR 4.8
>1 6 <0.0001 6 <0.0001 1.6 0.047
B symptoms
Absent 24 24 7
Present 19 0.009 NR 0.013 1.9 0.004
BM involvement
Absent NR NR 10.5
Present 19 0.077 24 0.088 2.7 0.0009
Era of diagnosis
<1990 19 24 4.3
1990–2000 NR NR 3.6
>2000 NR 0.079 NR 0.045 8.4 0.020
Stage
I–II NR NR 15
III–IV 19 0.015 24 0.038 3.7 0.003
Nodal sites
≤4 NR NR 10.5
>4 15 <0.0001 15 0.0006 2.5 <0.0001
LDH
Normal NR NR 7.8
Elevated NR 0.002 NR 0.001 1.9 0.174
Haemoglobin (g/dl)
<12 24 24 7
≥12 19 0.005 NR 0.012 1.9 0.361
FLIPI
Low-risk NR NR 13.5
Intermediate 15 15 2.7
High-risk 19 <0.0001 NR 0.0001 1.9 <0.0001
β2MG
Normal NR NR 10.1
Elevated 14 0.0006 14 0.0002 2.4 0.003
ESR
≤30 mm/h 24 24 8.4
>30 mm/h NR 0.320 NR 0.320 1.9 0.350
Bulk (cm)
<7 NR NR 4.9
7 18 0.220 18 0.077 3.8 0.833
Histologic grade
1–2 24 24 4.9
3a–3b NR 0.517 NR 0.956 4.3 0.920
OS, overall survival; CSS, cause-specific survival; PFS, progression-free survival; ECOG PS, Eastern Cooperative Oncology Group performance status; BM,
bone marrow; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase; β2MG, β2-microglobulin; ESR, erythrocyte
sedimentation rate.
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all groups of age seeing their lifespan shortened because of the
disease. Also, our data indicate that prognostic factors useful in
the whole population of patients with FL also apply to younger
patients, and that lymphoma-speciﬁc survival is similar in
young adults and in patients aged 40–60, suggesting that FL in
young adults, differently from paediatric FL [21, 22], does not
represent a distinct entity that needs to be treated differently.
However, prospective studies are needed to delineate the clinical
and biological diversity of FL across all age groups.
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Table 7. Multivariate analysis by Cox model for PFS in the
population of FL patients aged ≤40 years old
HR SE Z P-value 95% Confidence
interval
FLIPI 2.03 0.31 4.63 <0.0001 1.50 2.73
Era of diagnosis 0.69 0.12 −2.16 0.031 0.49 0.97
PFS, progression-free survival; HR, hazard ratio; SE, standard error;
FLIPI, Follicular Lymphoma International Prognostic Index.
Table 5. Multivariate analysis by Cox model for OS in the
population of FL patients aged ≤40 years old
HR SE Z P-value 95% Confidence
interval
FLIPI 2.85 0.70 4.21 <0.0001 1.75 4.63
Era of diagnosis 0.57 0.17 −1.85 0.064 0.31 1.03
OS, overall survival; FL, follicular lymphoma; HR, hazard ratio; SE,
standard error; FLIPI, Follicular Lymphoma International Prognostic
Index.
Table 6. Multivariate analysis by Cox model for CSS in the
population of FL patients aged ≤40 years old
HR SE Z P-value 95% Confidence
interval
FLIPI 2.65 0.69 3.77 <0.0001 1.59 4.41
Era of diagnosis 0.53 0.16 −2.04 0.042 0.29 0.97
CSS, cause-specific survival; FL, follicular lymphoma; HR, hazard ratio;
SE, standard error; FLIPI, Follicular Lymphoma International Prognostic
Index.
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